What is the role of reirradiation in the management of locoregionally relapsed non small-cell lung cancer?

Lung Cancer. 2020 Aug:146:263-275. doi: 10.1016/j.lungcan.2020.06.017. Epub 2020 Jun 17.

Abstract

The prognosis of lung cancer patients has improved in the last few years. Despite definitive therapy, local recurrence or a second primary tumour can occur in many patients within previously irradiated areas. Recent developement of more accurate techniques in radiation oncology allows delivery of high radiation dose to the tumor with the aim of improving local control, delaying disease progression and in some cases even curing. Nevertheless, the use of high dose in the reirradiation setting is not without risks, especially when treatment volumes overlap with previously irradiated tissues. The risk of adverse effects must be balanced with the choice of an effective treatment by selecting suitable candidates and the best radiation technique. In this systemic review efficacy and toxicity of reirradiation in locoregionally recurrent non-small-cell lung cancer is extensively discussed. Results indicate that reirradiation might be beneficial in well-selected patients. Prospective and high quality studies are necessary in this field.

Keywords: Locoregional relapse; Particle therapy; Reirradiation; Stereotactic body radiotherapy; Survival outcome; Toxicity.

Publication types

  • Review

MeSH terms

  • Carcinoma, Non-Small-Cell Lung* / radiotherapy
  • Humans
  • Lung Neoplasms* / radiotherapy
  • Neoplasm Recurrence, Local / radiotherapy
  • Prospective Studies
  • Radiotherapy Dosage
  • Re-Irradiation*